When is a bubble not a bubble but a fundamental and lasting shift in investor sentiment towards a sector? Despite repeated calls from the biotech bear camp that the end is in sight for the continued optimism enjoyed by the sector we continue to enjoy a burst of IPOs, fundraisings and M&A deals.
03 Aug 2015
Life Sciences Review - The Biotech Feast - after the party comes the hangover
Eden Research plc (EDEN:LON), 4.8 | SDI Group plc (SDI:LON), 56.0 | Genedrive Plc (GDR:LON), 5.9 | ImmuPharma plc (IMM:LON), 2.2 | Benchmark Holdings Plc (BMK:LON), 43.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Avacta Group PLC (AVCT:LON), 48.0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Life Sciences Review - The Biotech Feast - after the party comes the hangover
Eden Research plc (EDEN:LON), 4.8 | SDI Group plc (SDI:LON), 56.0 | Genedrive Plc (GDR:LON), 5.9 | ImmuPharma plc (IMM:LON), 2.2 | Benchmark Holdings Plc (BMK:LON), 43.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Avacta Group PLC (AVCT:LON), 48.0
- Published:
03 Aug 2015 -
Author:
Derren Nathan -
Pages:
10
When is a bubble not a bubble but a fundamental and lasting shift in investor sentiment towards a sector? Despite repeated calls from the biotech bear camp that the end is in sight for the continued optimism enjoyed by the sector we continue to enjoy a burst of IPOs, fundraisings and M&A deals.